Raymond James Maintains Strong Buy on DexCom, Lowers Price Target to $99
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Jayson Bedford maintains a Strong Buy rating on DexCom (NASDAQ:DXCM) but lowers the price target from $115 to $99.
October 25, 2024 | 5:44 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Raymond James maintains a Strong Buy rating on DexCom but lowers the price target from $115 to $99, indicating confidence in the stock despite a reduced target.
The Strong Buy rating suggests continued confidence in DexCom's performance, but the lowered price target reflects a more cautious outlook on its valuation. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100